triple hormone receptor agonist retatrutide for obesity Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more at our link in bio Retatrutide is a triple-agonist drug

**Current status:** Not FDA approved

Prevalence and prognostic significance of vitamin C deficiency in patients with acute upper gastrointestinal bleeding: a prospective cohort study

63 Valproic acid, benzodiazepines, except clobazam, and most of the newer AEDs, such as gabapentin, levetiracetam, tiagabine, zonisamide, vigabatrin, and lacosamide, are not enzyme inducers and have not been implicated in reducing contraceptive effectiveness

Also a substantial proportion of retatrutide patients (64-100%) were able to achieve a weight loss of 5% or more, a clinically significant threshold compared to just 27% in the placebo group